Table 3 Comparison analyses of clinical characteristics and treatment regimens
Characteristics | None CTC (n = 10) | OCT4−CTC (n = 12) | OCT4+CTC (n = 18) | P value |
|---|---|---|---|---|
Age, n (%) | Â | Â | Â | 0.118 |
 < 65 years | 3 (30.0) | 9 (75.0) | 10 (55.6) |  |
 ≥ 65 years | 7 (70.0) | 3 (25.0) | 8 (44.4) |  |
Sex, n (%) | Â | Â | Â | 0.567 |
 Female | 2 (20.0) | 5 (41.7) | 6 (33.3) |  |
 Male | 8 (80.0) | 7 (58.3) | 12 (66.7) |  |
ECOG PS score, n (%) | Â | Â | Â | 0.175 |
 0 | 3 (30.0) | 1 (8.3) | 0 (0.0) |  |
 1 | 5 (50.0) | 8 (66.7) | 13 (72.2) |  |
 2 | 2 (20.0) | 3 (25.0) | 5 (27.8) |  |
Lesion location, n (%) | Â | Â | Â | 0.666 |
 Intrahepatic | 6 (60.0) | 5 (41.7) | 11 (61.1) |  |
 Hilar | 4 (40.0) | 5 (41.7) | 5 (27.8) |  |
 Extrahepatic | 0 (0.0) | 2 (16.7) | 2 (11.1) |  |
Lymph node metastasis, n (%) | 6 (60.0) | 5 (41.7) | 16 (88.9) | 0.025 |
Distant metastasis, n (%) | 4 (40.0) | 8 (66.7) | 15 (83.3) | 0.065 |
TNM stage, n (%) | Â | Â | Â | 0.184 |
 III | 5 (50.0) | 4 (33.3) | 3 (16.7) |  |
 IV | 5 (50.0) | 8 (66.7) | 15 (83.3) |  |
Abnormal CA199, n (%) | 7 (70.0) | 9 (75.0) | 17 (94.4) | 0.205 |
Abnormal CA125, n (%) | 4 (40.0) | 7 (58.3) | 14 (77.8) | 0.151 |
Abnormal CEA, n (%) | 3 (30.0) | 3 (25.0) | 10 (55.6) | 0.206 |
Previous surgery, n (%) | 4 (40.0) | 1 (8.3) | 4 (22.2) | 0.237 |
Previous chemotherapy, n (%) | 2 (20.0) | 5 (41.7) | 12 (66.7) | 0.055 |
Previous radiotherapy, n (%) | 1 (10.0) | 1 (8.3) | 3 (16.7) | 0.847 |
Treatment line, n (%) | Â | Â | Â | 0.055 |
 First | 8 (80.0) | 7 (58.3) | 6 (33.3) |  |
 Second or above | 2 (20.0) | 5 (41.7) | 12 (66.7) |  |
ICI treatment, n (%) | 10 (100.0) | 12 (100.0) | 18 (100.0) | (-) |
ICI regimen, n (%) | Â | Â | Â | 0.876 |
 Camrelizumab | 5 (50.0) | 6 (50.0) | 8 (44.4) |  |
 Sintilimab | 2 (20.0) | 2 (16.7) | 5 (27.8) |  |
 Pembrolizumab | 1 (10.0) | 3 (25.0) | 3 (16.7) |  |
 Nivolumab | 2 (20.0) | 0 (0.0) | 1 (5.6) |  |
 Durvalumab | 0 (0.0) | 1 (8.3) | 1 (5.6) |  |
Combination treatment, n (%) | 10 (100.0) | 12 (100.0) | 18 (100.0) | (-) |
Combination treatment regimen, n (%) | Â | Â | Â | 0.174 |
 Capecitabine + oxaliplatin | 3 (30.0) | 6 (50.0) | 6 (33.3) |  |
 Lenvatinib | 1 (10.0) | 1 (8.3) | 8 (44.4) |  |
 Gemcitabine + cisplatin | 3 (30.0) | 2 (16.7) | 3 (16.7) |  |
 Gemcitabine + S-1 | 3 (30.0) | 3 (25.0) | 1 (5.6) |  |